Celldex Therapeutics (CLDX) Liabilities and Shareholders Equity (2010 - 2026)

Celldex Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $511.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 30.86% year-over-year to $511.3 million; the TTM figure through Mar 2026 stood at $2.4 billion (down 23.92% YoY), while the FY2025 annual figure was $583.0 million, down 26.42% from the prior year.
• Liabilities and Shareholders Equity was $511.3 million for Q1 2026 at Celldex Therapeutics, down from $583.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $868.8 million in Q1 2024 to a low of $280.3 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $554.3 million across 5 years, with a median of $511.3 million in 2026.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity surged 193.72% in 2024, then tumbled 30.86% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $352.7 million in 2022, then soared by 32.0% to $465.6 million in 2023, then soared by 70.17% to $792.3 million in 2024, then decreased by 26.42% to $583.0 million in 2025, then retreated by 12.3% to $511.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $511.3 million (Q1 2026), $583.0 million (Q4 2025), and $648.4 million (Q3 2025), per Business Quant data.